Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Meets the following conditions:~  * A clinical diagnosis of nonalcoholic fatty liver disease (NAFLD)~ * Screening magnetic resonance imaging - proton density fat fraction (MRI-PDFF) with ≥ 8% steatosis~ * Screening magnetic resonance elastography (MRE) with liver stiffness ≥ 2.5 kilopascal (kPa) OR~ * A historical liver biopsy within 12 months of screening consistent with NASH with fibrosis, but not cirrhosis, and~ * No documented weight loss \> 5% between the date of the liver biopsy and screening.~* Platelet count ≥ 150,000/mm\^3~* Albumin ≥ 3.3 g/dL~* Serum creatinine ≤ upper limit of normal (ULN)~Key Exclusion Criteria:~* Pregnant or lactating females~* Alanine aminotransferase (ALT) \> 5x upper limit of the normal range (ULN)~* Other causes of liver disease including autoimmune, viral, and alcoholic liver disease~* Cirrhosis of the liver~  * Prior history of decompensated liver disease, including ascites, hepatic encephalopathy, or variceal bleeding~* Body mass index (BMI) \< 18 kg/m\^2~* Uncontrolled diabetes mellitus (hemoglobin A1c \> 9% at screening)~* International normalized ratio (INR) \> 1.2 unless on anticoagulant therapy~* Total bilirubin \> 1 x ULN, except with diagnosis of Gilbert's syndrome~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GS-9674 30 mg (Type: EXPERIMENTAL): GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
- GS-9674 100 mg (Type: EXPERIMENTAL): GS-9674 100 mg + placebo to match GS-9674 30 mg for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).